Product name
Anti Cancer Sandwich - Ferrocenophanes against tumors from University of MunsterSummary
A new group of metallocenophanes as potent cytostatic drugsOrganization name
ProvendisProfile
Invention
The invention pertains to a new group of metallocenophanes as potent cytostatic drugs. The Ferrocenophanes were designed by reductive coupling of special carbonyl groups with iron sandwich compounds.
The new compounds obtained according to a new synthetic route represent potential candidates for the medical treatment of tumor diseases. Results on cell cultures (MTT Test) indicate pronounced cytotoxicity in pharmacologically relevant concent rations against L929 mouse fibroblasts and MCF-7 breast cancer cells.
Current status
The invention has been registered as a patent by the University of Münster and the Helmholtz-Centre for Infection Braunschweig. To the best of our knowledge, the method is not restricted by third party protective rights. In the name of University of Münster PROvendis searches for companies interested either to license the new compounds or to work in a joint-venture research project.
Benefits
- High yields
- Compounds new in pharmacological applications
- easy access to pure compounds
- positive results in cell culture
Contact
Dr. Joachim Kaiser
Tel: +49 208 94 105 23
jk@provendis.info
About PROvendis GmbH
PROvendis offers companies certified and patented innovations from 24 North Rhine-Westphalian universities. The core function of the enterprise is to market patentable and commercially exploitable inventions. PROvendis GmbH was founded in 2001 as a wholly owned subsidiary of Zenit GmbH, a management consultancy firm in cooperation with the state of North Rhine-Westphalia. Since January of 2002, PROvendis has been the service provider for the universities of the state of North Rhine-Westphalia. Within the scope of the BMBF commercialization campaign, the Federal Ministry for Education and Research (BMBF) supports the activities of PROvendis.
Description File
1756_ENG.pdf
print this page
